Capsule Weight Control: Fill Weight and 100% Checkweighing
Learn how to set capsule fill-weight controls, assess measurement coverage and build reviewable records without confusing capsule mass with ingredient content.

On this page · 12 sections
- 1What capsule weight control measures—and what it cannot prove
- 2Regulatory scope: US drugs, supplements and ICH method guidance
- 3Choose the mass basis, tare method and decision limits
- 4Process variables that move capsule fill weight
- 5Run the control plan from startup through batch disposition
- 6Build a traceable weight-control evidence model
- 7Recover safely from missing data and reject-system failures
- 8Three worked cases: tare, averages and count reconciliation
- 9Transfer the control strategy—not just the target weight
- 10Failure modes: misleading readings and inappropriate adjustments
- 11V5 Ultimate: supporting the batch evidence
- 12Implementation and review checklist
How does Capsule Weight Control (100% Checkweighing) apply to your shop floor?
Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.
01What capsule weight control measures—and what it cannot prove
Capsule Weight Control is the in-process measurement and management of capsule fill mass against defined limits through sampling, individual-capsule weighing, or both. Related terms include capsule checkweighing, which describes the weighing operation, and capsule fill weight, which describes the mass of material inside the shell. Here, the focus is filled capsules during manufacture—not the weight of a bottle, carton or shipping case.
| Term | Measured quantity | Typical decision | Boundary |
|---|---|---|---|
| Gross capsule weight | Shell plus contents | Classify against gross-weight limits | Includes shell mass |
| Net fill weight | Contents mass, excluding shell | Assess fill against target and limits | Depends on the shell-mass basis |
| In-process weight variation | Differences among capsule weights | Investigate spread or process drift | Sample results describe the measured units |
| 100% checkweighing | Individual weight of every capsule in a specified population | Classify each measured capsule | Coverage, not an accuracy specification |
| Content uniformity | Ingredient amount in individual dosage units | Assess unit-to-unit ingredient consistency | Distinct from total mass |
An individual weight result does not by itself demonstrate ingredient content: equally heavy fills can contain different ingredient proportions. Read weight uniformity alongside capsule content uniformity to distinguish mass consistency from dose consistency.
“100%” therefore needs a named population—for example, all capsules routed through a weighing station during a defined production interval. It does not mean perfect measurement or assured product quality. Capsules bypassing that station are outside that coverage claim, even if they belong to the same batch.
02Regulatory scope: US drugs, supplements and ICH method guidance
Start with the product category and destination market. Binding manufacturing requirements, guidance on pharmacopoeial methods, and site-level sampling decisions answer different questions; they should not become a single “capsule checkweighing standard.”
| Product and jurisdiction | Authority type | Provision | Operational relevance |
|---|---|---|---|
| US drugs | Binding US regulation | 21 CFR 211.110(a), (a)(1) | Written in-process procedures; capsule weight variation where appropriate. |
| US dietary supplements | Binding US regulation | 21 CFR 111.70(c)(1)–(3) | In-process specifications, documented basis and QC approval. |
| Medicinal products in ICH regions | ICH guidance | Q4B Annex 6, 2.1.1 | Conditional interchangeability of dosage-unit uniformity tests. |
| US medicinal-product context | FDA consideration within ICH guidance | Q4B Annex 6, 4.2 | Content Uniformity testing below the stated threshold. |
| EU medicinal-product context | EU consideration within ICH guidance | Q4B Annex 6, 4.3 | Describes mandatory applicability of Ph. Eur. monographs. |
US manufacturing requirements
For US drug manufacturing, 21 CFR 211.110(a) requires established and followed written procedures describing in-process controls and tests or examinations on appropriate samples from each batch. Section 211.110(a)(1) lists tablet or capsule weight variation among the controls to include “where appropriate.” This is not a universal requirement for 100% capsule checkweighing.
For US dietary supplements, 21 CFR 111.70(c)(1) requires in-process specifications at points, steps or stages in the master manufacturing record where control is necessary to help ensure specifications are met. Section 111.70(c)(2) requires documentation explaining why meeting in-process specifications together with component specifications will help ensure the specified supplement attributes. Under section 111.70(c)(3), QC personnel must review and approve that basis.
For supplement verification questions, check the current text of 21 CFR 111.75 for scope; keep verification distinct from establishing specifications under 111.70. Related reading on in-process controls and the master manufacturing record helps place these decisions in the production workflow.
Method guidance and regional considerations
ICH Q4B Annex 6, section 2.1.1 addresses conditional pharmacopoeial interchangeability, not in-process checkweigher specifications. Unless the 25 mg/25% threshold is met, using Mass/Weight Variation instead of Content Uniformity is not considered interchangeable across all ICH regions. Treat that threshold as a condition—not a complete eligibility rule or a fill-weight tolerance.
The FDA consideration in section 4.2 says Content Uniformity testing should be performed for items below that threshold. The EU consideration in section 4.3 describes mandatory applicability of Ph. Eur. monographs in the EU medicinal-product context. That is a regional statement within guidance, not a universal rule for supplements, foods, devices or chemicals.
As manufacturing practice, document sampling frequency, sample size and any decision to use 100% weighing separately from the legal applicability assessment. Justify those technical choices against the process and measurement risks rather than attributing them to the provisions above.
03Choose the mass basis, tare method and decision limits
Net fill mass = gross capsule mass − shell mass, using the same units throughout. An individual-shell determination uses the shell belonging to that capsule; subtracting representative shell tare produces an estimated net fill. Record which basis applies rather than labelling both results simply “fill weight.”
Method selection should account for capsule identity, retained fill residue, shell handling and moisture:
- Paired measurements: weigh the empty shell and subsequently the filled capsule, preserving identity and controlling handling or moisture changes between measurements.
- Emptying and reweighing: weigh the filled capsule, remove its contents and reweigh its shell. Establish suitability: retained residue raises apparent tare, while shell damage or moisture change can alter the result.
- Representative shell-lot tare: subtract an average from a defined shell sample. This supports estimation but cannot identify each capsule’s actual shell mass; individual shell variation contributes uncertainty.
For US drugs, 21 CFR 211.110(b) requires valid in-process specifications to be consistent with final drug-product specifications. They must derive from previous acceptable process averages and variability estimates where possible, with suitable statistical procedures applied where appropriate.
In a practical control plan, distinguish product acceptance limits, which classify results, from process warning limits, which trigger investigation, and adjustment targets, which guide centring. Define specification boundaries and tolerance bands: units, whether endpoints are inclusive or exclusive, and whether classification precedes rounding. Specify an indeterminate category and response—such as holding affected capsules for assessment—rather than forcing an uncertain result into pass or fail.
Display resolution is the smallest displayed increment, not proof of accuracy. Measurement uncertainty describes the doubt associated with the result, including relevant weighing and tare contributions. Review calibration alongside tare verification, then assess measurement uncertainty against the tolerance. Demonstrate suitability at the intended operating speed and near decision limits; a readable display or satisfactory static check alone does not establish dynamic sorting performance.
04Process variables that move capsule fill weight
Treat the following as candidate influences, not automatic critical process parameters. Use risk assessment and product-specific process evidence to establish which variables are critical and how their operating ranges interact within the proposed design space.
- Material properties: bulk density changes the mass delivered by a volumetric dose. Powder flow, segregation and moisture can alter feeding consistency; segregation also warrants investigation of composition, not just weight.
- Dosing mechanism: examine dose-volume settings, tamping depth or force, and vacuum where applicable. Machine speed changes the time available for filling and powder consolidation. Hopper replenishment can disturb powder level and packing.
- Capsule presentation: inspect body alignment, opening and seating. Intermittent mispresentation can cause incomplete filling or powder loss; shell-mass changes can shift gross-weight readings.
- Operating environment: compare humidity, temperature and static conditions with established process experience, particularly when powder behaviour changes during a run.
Investigate location and variability separately using statistical process control. A shifted mean suggests a systematic change: check material transitions, settings and replenishment timing. Greater spread suggests inconsistent delivery: inspect intermittent feed, tooling or presentation problems. These are hypotheses, not diagnoses. Compare trends by time and, where identifiable, dosing station, lane or other machine position; a pooled average can hide a local problem. Target checks to the affected interval or position before broadening the investigation.
Before changing speed, compaction or dosing conditions solely to improve the weight trend, assess relevant formulation effects, including content uniformity, disintegration and dissolution. A tighter weight distribution alone does not establish acceptable formulation performance.
05Run the control plan from startup through batch disposition
Use a product-specific operating sequence with named responsibilities. The workflow below is an illustrative industry-practice model, not a universal sampling schedule. Assign startup review, adjustment authority and restart approval before production begins.
Current control plan → line clearance and setup → startup measurements → authorised routine running → event checks and exception handling → documented restart, when needed → batch evidence review → human disposition.
- Prepare the line. Select the current control plan; confirm the batch, product and shell lot. Complete line clearance, including checks for previous-product remnants and spillage and cross-contamination risks. Record the operator and setup identifiers.
- Establish measurement readiness. Check instrument calibration and verification status, establish the approved tare basis, and confirm the recipe target, warning limits and acceptance limits. Where automatic rejection is used, challenge the reject path and confirm that challenged capsules reach the intended destination.
- Review startup results. Have the designated reviewer assess initial measurements and challenge results before authorising routine running. Resolve discrepancies rather than treating the first acceptable reading as sufficient evidence of stable operation.
- Cover production risks. Define in-process sampling around startup, routine running, material replenishment, adjustment, interruption and restart. Justify sample sizes and intervals from process variability and the consequences of undetected drift. For individual weighing, apply the coverage definition above: identify the batch segment, lanes and operating periods entering the measurement path; use counters, routing status and event logs to identify bypasses or unmeasured output.
- Respond and restart deliberately. For warnings, out-of-limit results or sustained trends, follow the plan’s escalation rules. Assess the affected interval, segregate potentially affected output where appropriate, investigate the cause, and obtain the designated person’s authorisation before adjustment. Record the change, restart checks and restart decision.
Close with human review of the batch record for disposition. For US drugs, equipment classification is not quality control unit approval: 21 CFR 211.110(c) requires appropriate testing of in-process materials for identity, strength, quality and purity, and their approval or rejection by the quality control unit during production.
- Select planConfirm product, batch, mass basis and limit version.
- Verify setupCheck tare method, instrument status and reject challenge.
- Start runApprove initial checks before routine collection begins.
- Measure unitsCapture weights with device, sequence and time identifiers.
- Control exceptionsIsolate suspect units and identify affected production.
- Reconcile recordsResolve missing events, reject counts and physical quantities.
- Review dispositionAn authorised person documents the batch decision.
06Build a traceable weight-control evidence model
Use a recommended record model that reconstructs each measurement, its classification and subsequent handling. These are design recommendations, not universal statutory fields. When organising electronic batch records for a paperless shop floor, retain stable identifiers linking the following records.
| Record | Recommended content |
|---|---|
| Run context | Batch and run identity, product, shell lot, control-plan version and device identifier. |
| Measurement event | Event identifier, measurement time and sequence, mass basis, units and measured values. |
| Calculation and classification | Tare basis and referenced measurements, calculation version, calculated net fill, applicable limits and result classification. |
| Handling event | Linked reject command, removal confirmation or unresolved status, physical container identifier and subsequent disposition. |
Keep measured inputs separate from calculated net-fill values. Preserve the original readings and the tare basis—including whether tare was individual or sampled—so a reviewer can reproduce the reported result. Include recalculation history in the data integrity risk assessment.
Illustrative data-model diagram, independent of any application: Batch → Run → Measurement → Calculation/classification → Handling events → Container → Disposition. Each measurement references its device and control-plan version; each calculation references its tare basis.
A reject command records an instruction, not proof of physical removal. Link the rejected-weight decision to confirmation evidence or an explicit unresolved status. Preserve container-level lot traceability through subsequent handling and disposition.
Individual events support reconstruction; batch summaries support review of trends, counts and exceptions. Retain links from each summary to its underlying events and identify the covered run interval, so aggregation does not erase investigation context.
Control plan
Defines the measurement basis and approved decision limits.
- plan_id
- plan_version
- mass_basis
- target_mg
- lower_limit_mg
- upper_limit_mg
Production Run
Links execution to equipment, materials and control settings.
- run_id
- batch_id
- device_id
- plan_id
- plan_version
- shell_lot_id
Weight Event
Preserves measurement inputs, calculation basis and result classification.
- weight_event_id
- run_id
- sequence_no
- event_time
- gross_weight_mg
- shell_tare_mg
- fill_weight_mg
- tare_basis
- result_code
Reject Event
Connects a weight decision to physical reject handling.
- reject_event_id
- weight_event_id
- command_time
- confirmation_time
- reject_container_id
- status
Human Review
Records exception assessment and an accountable disposition decision.
- review_id
- run_id
- exception_refs
- reviewer_id
- reviewed_at
- disposition
07Recover safely from missing data and reject-system failures
As integration practice, define an interface contract connecting the capsule filler, weighing device, reject controller and record system. Include stable run identifiers, source-device identity, sequence numbers, units, mass basis, original event timestamps, recipe version and acknowledgement status. Distinguish message receipt from confirmed physical rejection when designing manufacturing-system interfaces.
Detect duplicates using run, source and sequence identifiers; flag conflicting payloads rather than silently overwriting them. Handle out-of-order events explicitly and make buffered replay safe to repeat without double-counting. Preserve original event time separately from receipt time. Apply corrections through a controlled record retaining the original value, reason, author and approval where required by procedure.
- Contain the fault: communication loss, restart, unreadable measurements, full reject containers or failed reject confirmation should trigger the defined stop or diversion response.
- Bound the affected interval from the last demonstrated reliable measurement and reject operation to verified restoration. Segregate uncertain output, including material in transit, using a traceable quarantine hold.
- Reconcile missing, duplicate and replayed events against physical quantities in accepted, rejected and held output. Investigate unexplained differences through the deviation workflow.
- Verify measurement and rejection functions before resuming; obtain an authorised human decision on affected material. Successful message replay restores records, not proof of physical segregation or product acceptance.
For US drug manufacture, 21 CFR 211.110(d) requires rejected in-process materials to be identified and controlled under a quarantine system designed to prevent their use in manufacturing or processing operations for which they are unsuitable.
08Three worked cases: tare, averages and count reconciliation
These hypothetical pharmaceutical and dietary-supplement capsule examples illustrate measurement reasoning, not regulatory acceptance criteria or machine performance.
Case 1: Shell-tare sensitivity
For a pharmaceutical capsule, assume gross mass is 470 mg and representative shell tare is 70 mg. Estimated net fill is 470 − 70 = 400 mg.
If that individual shell actually weighs 65–75 mg, net fill ranges from 470 − 75 = 395 mg to 470 − 65 = 405 mg. The heavier shell gives the lower fill estimate. This is a sensitivity illustration, not a measured confidence interval: it shows how shell mass changes the interpretation of an unchanged gross reading. Keep shell and fill contributions separate when constructing a net-versus-gross mass balance.
Case 2: A misleading mean
For dietary-supplement capsules, assume four net-fill measurements: 370, 390, 410 and 430 mg. Hypothetical inclusive acceptance limits are 380–420 mg. Four units are chosen for arithmetic clarity, not as a recommended production sampling plan.
The total is 1,600 mg; the mean is 1,600 ÷ 4 = 400 mg. Nevertheless, 370 mg is below the lower limit and 430 mg exceeds the upper limit. Two of four measurements are outside limits. An on-target mean therefore does not demonstrate that individual results satisfy the stated limits.
Case 3: Interrupted electronic capture
For a pharmaceutical capsule run, assume 120,000 capsules entered a defined accounting boundary: 118,800 classified as accepted, 700 underweight, 400 overweight and 100 unclassified and physically held. Assume no additional samples, transfers or losses.
Counts reconcile: 118,800 + 700 + 400 + 100 = 120,000 capsules. Valid weight classifications cover only 118,800 + 700 + 400 = 119,900 capsules. Reconciled counts do not establish complete recorded weighing coverage.
Separately confirm that the 1,100 classified rejects were physically diverted and segregated; a classification alone does not confirm routing. For production reconciliation, additional samples, transfers or losses would need distinct accounting entries, with transfer direction defined and double-counting prevented. Their weight-classification status remains a separate question.
09Transfer the control strategy—not just the target weight
As technology-transfer practice, treat a move to another machine, scale, site or shell supply as a comparison of operating performance. An unchanged formulation or nominal fill target does not establish equivalence. The technology-transfer plan should identify differences that could affect measurement or capsule handling.
- Compare dosing mechanism, throughput, material feed and environmental conditions across sending and receiving operations.
- Reassess shell source and tare distribution, weighing-device response and reject-path timing at the intended operating speeds.
- Compare the measurement basis and distributions of results—not only averages—under the affected process conditions. Include event completeness and evidence that rejected capsules reach their intended destination.
Use change control to document which recipes and control-plan versions remain suitable and which need revision. Define acceptance evidence before trials, linking it to process validation and performance qualification where appropriate. Before routine use, have the receiving operation’s designated owners review approved recipes, control-plan versions, relevant operator training and trial results against those criteria; resolve gaps rather than carrying assumptions forward.
10Failure modes: misleading readings and inappropriate adjustments
These troubleshooting patterns are industry practice, not diagnoses established by weight data alone. Confirm each hypothesis through product-specific investigation; apply the decision rules in the limits section before adjusting settings.
| Failure mode | Observable signal | Immediate assessment | Preventive control |
|---|---|---|---|
| Exterior powder or shell fragments | High readings; visible residue | Inspect capsules and weighing surfaces; distinguish adhering material from fill. | Controlled dedusting and cleaning checks. |
| Damaged or leaking capsules | Low readings; loose powder; split shells | Inspect closure and handling points; assess affected product separately. | Closure checks and handling inspections. |
| Vibration or air movement | Unstable readings correlated with nearby activity | Check mounting, airflow and repeatability under controlled conditions. | Qualified location, isolation and airflow protection. |
| Station-specific variation hidden by pooled trends | Acceptable pooled mean; station-level differences | Separate results by station; inspect corresponding dosing components. | Retain station identity and review stratified trends. |
| Over-adjustment to random variation | Frequent setting reversals; oscillating results | Compare adjustment history with the approved decision rules. | Defined adjustment authority and post-adjustment observation. |
| Wrong mass basis in recipe | Persistent offset despite apparently stable filling | Check whether recipe targets and measured results use gross or net mass. | Recipe review with explicit mass-basis identification. |
Use FMEA to prioritize hypotheses for root-cause analysis. Connect recurring signals through out-of-trend handling to corrective and preventive action, with effectiveness checks tied to the confirmed cause.
11V5 Ultimate: supporting the batch evidence
As covered in execution, approval and release remain human decisions, with responsibility retained through the QA disposition step.
12Implementation and review checklist
Use these questions as a recommended readiness review of the decisions above, not as a substitute for applicable requirements or authorised quality review.
- Scope: Are the applicable product category, jurisdiction and control-plan version identified?
- Measurement: Are the mass basis, justified tare method and current decision limits documented? Is measurement equipment suitable for the intended range and operating conditions?
- Coverage: Does the plan define production coverage, including startup, interruptions and the end of the run?
- Ownership: Are named roles responsible for startup approval, adjustments, reject challenges, exception containment, restart authorisation and final disposition?
- Traceability: Does the batch record connect the control-plan version to measurements, physical reject handling, reconciled quantities and unresolved exceptions?
- Reassessment: Are shell-lot changes and equipment changes explicit change-control triggers? Do data outages and repeat failure patterns trigger a defined reassessment?
- Disposition: Does the batch release checklist identify outstanding weight-control questions and the authorised person responsible for resolving them?
Finish with a documented readiness decision for the next activity: proceed or hold. List each unresolved item, its responsible person and the evidence needed before proceeding. Route blocking gaps to the designated approver rather than treating checklist completion as approval.
Frequently asked questions
Q.What evidence would justify reducing manual net-fill checks after introducing individual-capsule checkweighing?+
Build a product-specific comparison of individual gross weights against destructive net-fill measurements across shell lots, operating speeds, startups and anticipated process disturbances. Assess bias, variability, shell-tare effects, missed measurements and physical reject performance—not just agreement between batch averages. Challenge the system near both limits. Use that evidence in a process validation assessment to justify the remaining manual-check frequency and triggers for increased sampling. A fill weight checker checking every capsule does not, by itself, establish that gross weight reliably predicts net fill.
Q.How should a shell-supplier change affect tare assessment and an existing gross-weight recipe?+
Treat the change as a reason to reassess shell mass distribution, not simply substitute a new average tare. Compare representative old and new shell lots under relevant storage and production conditions, including shell moisture. Evaluate whether the existing gross-weight limits still distinguish acceptable from unacceptable net fills across the observed shell variation. Document the assessment through change control, including any recipe revision and confirmation checks. A target shift alone may not address a wider or less stable shell-mass distribution.
Q.Is a capsule exactly on a weight limit accepted before or after rounding?+
Define this in the approved decision rule before production. Specify the comparison precision, whether each boundary is inclusive, and whether any measurement-uncertainty guard band applies. For a recipe using inclusive limits and unrounded stored values, compare the stored measurement first; a rounded display is not the acceptance value. Challenge values just below, exactly at and just above each boundary. The weighing tolerance band should distinguish product limits from machine decision thresholds so operators do not resolve borderline results by discretionary rounding.
Q.What additional evidence matters when a capsule contains a low-dose active ingredient?+
Assess active concentration and its distribution, not merely total fill mass. Useful evidence includes individual-capsule assays across the run, blend or pellet segregation studies, sampling-method suitability and analytical sensitivity at the intended dose. For pharmaceutical compendial-method selection, the FDA consideration in ICH Q4B Annex 6, section 4.2 recommends Content Uniformity testing for items below the 25 mg/25% threshold. That guidance is not a universal supplement rule. Link weight trends to capsule content uniformity results when investigating whether mass control tracks active delivery.
Q.Can underweight or overweight capsules be opened and refilled rather than discarded?+
Do not treat opening and refilling as an ordinary machine adjustment. For drug manufacturing, 21 CFR 211.110(d) requires rejected in-process materials to be identified and controlled under quarantine to prevent unsuitable use. That provision does not itself authorize refilling. Before considering recovery, assess contamination, ingredient segregation, material identity, exposure time and shell damage through a documented, product-specific disposition process. Keep rejected capsules segregated while quality personnel determine whether an authorized recovery route exists and what testing and human approval it needs.
Q.How should destructive samples and setup capsules appear in the batch reconciliation?+
Record destructive samples and setup capsules as distinct, non-overlapping disposition categories rather than hiding them within an unexplained yield loss. Capture quantities, units, collection stage and final destination; separate intact capsule counts from recovered fill or shell masses. If setup material is returned, record the return without counting it as both consumed and discarded. Align in-process reconciliation with the batch's defined accounting boundary, and use net-versus-gross reconciliation to avoid comparing powder input directly with finished capsules that include shell mass.
Q.What should a contract manufacturer provide when a customer receives only a weight-summary report?+
Agree on a supporting data package: batch and equipment identifiers, recipe version, limits and decision rules, measurement coverage, time-resolved results, reject counts, interruptions, challenge checks, deviations and reconciliation. Include the shell-tare basis where net fill is inferred. Specify access to underlying records and relevant change history rather than accepting averages alone. A batch record index can locate supporting documents, while an audit-trail review workflow can identify parameter changes requiring explanation. Define these deliverables in the manufacturing or quality agreement.
Q.When should repeated weight-related deviations lead to a control-strategy review rather than another machine adjustment?+
Escalate when the same failure returns after corrective action, adjustment frequency rises, or acceptable averages conceal recurring tails and rejects. Compare events by shell lot, blend properties, humidity, speed, tooling position and operator intervention to identify shared causes. Review whether specifications, sampling, tare assumptions, maintenance and detection methods still fit the process. A control-strategy review is appropriate when adjustments repeatedly restore output without explaining instability. Define effectiveness measures and an observation period before concluding that the underlying cause has been controlled.
Primary sources
Want to see how Capsule Weight Control (100% Checkweighing) could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.
